Altimmune
Compare Altimmune…Clinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AltimmuneClinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
Basic shares represent total shares issued. Diluted shares include potential shares from stock options, convertible securities, and other equity awards.
Q2 2016 — Q1 2026